RxDoctor Payments Data

Javier Alfonso, MD

Nephrology · Miami, FLNPI 1093952442

Payments from drug & device makers

$6,411in general payments, 2019–2025

Across 122 payments — averaging $52.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$1K
  • Boehringer Ingelheim$417
  • Calliditas Therapeutics US Inc.$298
  • Aurinia Pharma U.S., Inc.$277
  • Novo Nordisk$268
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$6,384100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,411 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$41,501
Medicare patients
83
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol322$214,413
JardianceEmpagliflozin122$78,014
LokelmaSodium Zirconium Cyclosilicate74$61,300
KerendiaFinerenone30$20,525
VeltassaPatiromer Calcium Sorbitex18$19,068
DapagliflozinDapagliflozin Propanediol17$7,410
Sevelamer Carbonate13$1,405
Bumetanide67$998
Calcium Acetate12$935
Calcitriol26$272
Amlodipine Besylate69$250
Irbesartan21$241
Losartan Potassium32$175
Lisinopril23$117
Clonidine Hcl36$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$2,112$275,712396 claims
Boehringer IngelheimJardiance$417$78,014122 claims
BayerKerendia$1,142$20,52530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →